Blind People Offered Hope of Seeing Again After Stem Cell Breakthrough Remakes Retinal Blood Vessels
When injected into mice with retinal disease, the special retinal blood cells integrated into the damaged tissue to ...
Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study designFDA indicates Opus Genetics may submit a BLA based on ...
Belite Bio, Inc (NASDAQ: BLTE) ('Belite Bio®” or the 'Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today ...
From memorable patient encounters to emerging therapies, OT talks with practitioners about opportunities and challenges in ...
Inherited retinal degenerations are a diverse group of genetic disorders that result in progressive vision loss. Advances in ...
FDA expands Casgevy CRISPR gene therapy to children aged 2+ with sickle cell disease and beta thalassemia, enabling earlier ...
Casgevy is the first gene therapy approved for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 2 and older.
Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results